BioCentury | Apr 28, 2017
Finance

1Q17 public-private partnership roundup

...million; $1.6 million plus $5.4 million in milestones Phase I 2012 Cidara Therapeutics Inc. (NASDAQ:CDTX) CD201...
...Cidara Therapeutics Inc. received $3.9 million upfront and $3 million in milestone payments to move CD201...
...London, U.K. Targets LpxC - UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase Mark Zipkin and Winnie Pong, Staff Writers ACAM2000 ALVAC HIV vaccine Alvac-HIV CD201 HVTN...
BioCentury | Nov 9, 2015
Clinical News

CAR-T CD20: Phase IIa data

An open-label, Chinese Phase IIa trial in 10 patients with CD20-positive advanced B cell NHL showed that CBM-CD20.1 led to an ORR of 80%, including 5 complete remissions and 3 partial remissions, plus 2 cases...
BioCentury | Apr 6, 2015
Clinical News

CAR-T CD20: Clinical trial data

An open-label, Chinese clinical trial in 7 patients with CD20-positive chemotherapy-refractory advanced DLBCL showed that CAR-T CD20 led to an overall response rate (ORR) of 75% in 4 evaluable patients with bulky tumor burden. In...
Items per page:
1 - 3 of 3